Movement Disorders Conferences | Europe | Asia | Middle East | Canada | Japan | Australia | USA

Movement Disorders

Movement disorders, a neurological condition, in which an abnormal increase or reduction in movement is observed, which is voluntary or involuntary. Movement disorder is divided into two categories:

Hyperkinetic movement disorders: It is the involuntary movement which hinders the normal movement of motor activity of the body. It refers to repetitive movement or dyskinesia.

Hypokinetic movement disorders: It is the slow motion of the body parts or motor activity. As it refers to hypokinesia - reduced amplitude of movement, akinesia – lack of movement, rigidity, and bradykinesia – slow movement.

Some movement disorders are:

Ataxia
Cervical Dystonia
Chorea
Huntington's disease
Multiple system atrophy
Parkinson's disease

Treatment of these disorders depends on movement disorders.

Sub-tracks:

Parkinson's disease
Progressive Supranuclear Ophthalmoplegia
Dystonia
Blepharospasm
Parkinson plus syndromes
Secondary Parkinsonism
Cerebral palsy

Market Analysis: The Movement Disorders market is projected for substantial growth between 2025 and 2030, driven by increasing global prevalence, an aging population, and continuous advancements in diagnostics and therapeutics. The overall market is estimated to reach $11,067 million by 2030, reflecting a CAGR of 7.90% during the 2024-2030 period.Within this, individual segments show varied growth. The Parkinson's Disease Treatment Market is expected to grow at a CAGR of 3.58% to 7.45%. The Huntington's Disease Treatment Market is poised for significant expansion, with CAGRs broadly ranging from 7.8% to an impressive 23.8%, fueled by substantial R&D in disease-modifying therapies like gene therapies. The Dystonia Treatment Market is projected for a CAGR of 5.5% to 5.81%, with cervical dystonia specifically at 6.7% CAGR, driven by botulinum toxin injections.

For Essential Tremor Treatment, the overall market is forecast for a 5.3% CAGR, but Deep Brain Stimulation Devices for this condition show a robust 10.3% CAGR. The Restless Legs Syndrome (RLS) Treatment Market is estimated to grow at approximately 5.21% CAGR, potentially reaching up to 7%. This robust market momentum is supported by ongoing advancements in medical technology, including AI-based diagnostics and wearables, increased R&D, and rising awareness leading to earlier diagnoses.

Tracks